Stocklytics Platform
Asset logo for symbol MRNS
Marinus Pharmaceuticals
MRNS45
$0.32arrow_drop_down3.72%-$0.01
Penny Stock
Asset logo for symbol MRNS
MRNS45

$0.32

arrow_drop_down3.72%

Income Statement (MRNS)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
EBIT-$30.28M-$35.82M-$35.43M-$31.83M-$29.31M
EBITDA-$30.14M-$35.69M-$35.31M-$31.64M-$29.13M
gross Profit$7.18M$6.79M$6.17M$6.88M$5.69M
NET Income-$35.82M-$38.66M-$41.76M-$32.97M-$31.93M
total Revenue$8.05M$7.67M$7.19M$7.33M$6.08M

Balance Sheet (MRNS)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
cash Equivalents-----
net Debt$31.21M$8.26M-$10.21M-$66.27M-$22.01M
stockholders Equity-$47.34M-$16.43M$16.76M$54.53M$57.33M
total Assets$87.08M$137.35M$170.90M$200.80M$201.20M
total Debt$95.89M$112.51M$110.35M$74.15M$105.77M
total Liabilities$134.42M$153.78M$154.14M$146.26M$143.86M

Cash Flow (MRNS)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
financing Cash Flow-$17.69M$257.00K$661.00K$25.90M$237.00K
free Cash Flow-$30.87M-$37.46M-$27.02M-$25.25M-$24.35M
investing Cash Flow----$5.00M
operating Cash Flow-$30.84M-$37.46M-$26.99M-$25.17M-$24.35M

Marinus Pharmaceuticals (MRNS) Financials

The income statement of Marinus Pharmaceuticals Inc (MRNS) provides a comprehensive overview of the financial performance of the company. It outlines the revenues, expenses, and net income for a specific period. The income statement helps investors and analysts evaluate the profitability and efficiency of the company's operations. By analyzing the different components of the income statement, stakeholders can assess the company's growth potential and financial stability. The income statement includes information on gross profit, operating expenses, interest expense, taxes, and net income. This data is crucial for making informed investment decisions and understanding the financial health of Marinus Pharmaceuticals Inc.
The EBIT (Earnings Before Interest and Taxes) of Marinus Pharmaceuticals Inc (MRNS) is a critical financial metric that measures the company's operating profitability. It is calculated by subtracting operating expenses, excluding interest and taxes, from the gross profit. The EBIT provides insights into the company's ability to generate profits from its core business operations, regardless of financing and tax considerations. It helps investors and analysts evaluate a company's operating performance and compare it to its peers. A positive EBIT indicates that the company is profitable at an operating level, while a negative EBIT suggests potential financial challenges. Marinus Pharmaceuticals Inc's EBIT serves as an important indicator of its operational efficiency and profitability.
EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is another crucial financial metric for evaluating the operational performance of Marinus Pharmaceuticals Inc (MRNS). It provides a comprehensive picture of a company's earnings potential by excluding non-operating expenses like interest, taxes, and depreciation. EBITDA is calculated by adding back interest, taxes, depreciation, and amortization to the EBIT. This metric helps investors assess a company's ability to generate cash flow from its operations and compare it to its peers. By focusing on the core operations, EBITDA allows for a more accurate evaluation of a company's profitability and financial strength. Marinus Pharmaceuticals Inc's EBITDA is a key indicator of its operational efficiency and ability to generate cash flow.
Gross profit is a vital component of the financial performance of Marinus Pharmaceuticals Inc (MRNS). It represents the revenue remaining after subtracting the cost of goods sold (COGS). Gross profit reflects the company's ability to generate revenue and control production costs. Comparing gross profit over different periods allows investors and analysts to assess both the company's pricing power and cost management. A consistent increase in gross profit indicates revenue growth and efficient cost management, which are indicators of a healthy and sustainable business. Marinus Pharmaceuticals Inc's gross profit provides valuable insights into its ability to generate revenue and control production costs.
The net income from stockholders is a crucial part of Marinus Pharmaceuticals Inc's (MRNS) financial picture. It represents the profit that remains after all costs and expenses, including interest and taxes, have been deducted from the company's total revenues. Net income provides critical insights into a company's overall profitability and financial health. Positive net income indicates that the company is generating profits, while negative net income suggests potential financial difficulties. Analyzing net income helps investors and analysts evaluate Marinus Pharmaceuticals Inc's ability to generate consistent profits and assess its future growth potential.
Total revenue is a key financial metric that measures the total amount of money generated by Marinus Pharmaceuticals Inc (MRNS) from its operations. It includes all sales of goods and services and is a vital indicator of a company's ability to generate income. By analyzing the trend of total revenue over time, investors and analysts can assess the company's growth potential and financial stability. Increasing total revenue indicates a healthy and expanding business, while declining revenue may suggest challenges and potential financial difficulties. Marinus Pharmaceuticals Inc's total revenue provides valuable insights into its sales performance and revenue-generating capabilities.
The balance sheet of Marinus Pharmaceuticals Inc (MRNS) provides a snapshot of the company's financial position at a specific point in time. It includes information about the company's assets, liabilities, and stockholders' equity. The balance sheet is divided into three sections: assets, liabilities, and stockholders' equity. Assets represent the company's resources, including cash, investments, property, and equipment. Liabilities include the company's debts and other obligations. Stockholders' equity represents the owners' interest in the company. By analyzing the balance sheet, investors and analysts can assess the company's financial stability and its ability to meet its obligations.
Cash equivalents are a vital component of Marinus Pharmaceuticals Inc's (MRNS) financial position. They represent highly liquid assets that can be readily converted into cash. Cash equivalents include short-term investments and highly liquid securities with a maturity period of three months or less. They serve as a measure of the company's short-term liquidity and financial flexibility. Having a significant amount of cash equivalents indicates that the company can meet its short-term obligations and fund its operations. Marinus Pharmaceuticals Inc's cash equivalents provide insights into its ability to manage short-term cash flow needs and potential investment opportunities.
Net debt is an essential financial metric for evaluating Marinus Pharmaceuticals Inc's (MRNS) financial health. It represents the company's total debt minus its cash and cash equivalents. Net debt reflects the company's ability to meet its outstanding financial obligations and indicates its overall financial strength. A high net debt level can indicate potential financial risk and limited flexibility. Conversely, a low net debt level suggests financial stability and a stronger position to invest in growth opportunities. Analyzing Marinus Pharmaceuticals Inc's net debt allows investors and analysts to assess the company's ability to manage its debt load and navigate potential financial challenges.
Stockholders' equity is a key component of Marinus Pharmaceuticals Inc's (MRNS) financial position. It represents the residual interest in the company's assets after deducting liabilities. Stockholders' equity is a measure of the shareholders' claim on the company's assets and reflects the company's net worth. It includes common stock, additional paid-in capital, retained earnings, and accumulated other comprehensive income. By analyzing stockholders' equity, investors and analysts can evaluate the company's financial health, valuation, and ability to generate returns for shareholders. Marinus Pharmaceuticals Inc's stockholders' equity provides valuable insights into its overall financial position and shareholder value.
Total assets are a crucial measure of Marinus Pharmaceuticals Inc's (MRNS) financial strength and value. They represent the company's resources and include current assets, such as cash, inventory, and accounts receivable, as well as long-term assets, such as property, plant, and equipment. Total assets provide a comprehensive overview of a company's financial position and its ability to generate future cash flows. By analyzing the trend of total assets over time, investors and analysts can assess the company's growth potential and its ability to meet its financial obligations. Marinus Pharmaceuticals Inc's total assets serve as a key indicator of its overall financial strength and value.
Total debt is a critical financial metric for evaluating Marinus Pharmaceuticals Inc's (MRNS) financial health. It represents the company's outstanding debt obligations, including long-term and short-term debt. Total debt reflects the company's ability to meet its financial obligations and its overall leverage. A high total debt level may pose financial risk and limit the company's flexibility in pursuing growth opportunities. Conversely, a low total debt level suggests financial stability and a stronger ability to invest in future growth. Analyzing Marinus Pharmaceuticals Inc's total debt allows investors and analysts to evaluate its financial leverage and assess potential risks. It provides valuable insights into the company's ability to manage its debt load and navigate potential financial challenges.
Total liabilities are a crucial component of Marinus Pharmaceuticals Inc's (MRNS) financial position. They represent the company's obligations and include both current liabilities, such as accounts payable and accrued expenses, and long-term liabilities, such as deferred tax liabilities and long-term debt. Total liabilities provide insights into the company's financial obligations and its overall financial health. Analyzing the trend of total liabilities over time helps investors and analysts assess the company's ability to meet its financial obligations and its level of financial risk. Marinus Pharmaceuticals Inc's total liabilities serve as an important measure of its financial strength and stability.
The cash flow statement of Marinus Pharmaceuticals Inc (MRNS) provides insights into the company's cash inflows and outflows over a specific period. It includes information on operating activities, investing activities, and financing activities. Analyzing the cash flow statement helps investors and analysts assess the company's ability to generate cash, manage its cash flow, and meet its financial obligations. Positive cash flow from operating activities indicates that the company is generating cash from its core operations. Positive cash flow from investing activities suggests that the company is making strategic investments to support its growth. Positive cash flow from financing activities indicates that the company is effectively managing its capital structure and meeting its financing needs. Marinus Pharmaceuticals Inc's cash flow statement provides valuable insights into its financial performance and its ability to generate and manage cash.
The financing cash flow of Marinus Pharmaceuticals Inc (MRNS) represents the cash flow resulting from the company's financing activities. It includes cash inflows and outflows related to issuing and repurchasing stock, issuing and repaying debt, and paying dividends. Analyzing the financing cash flow helps investors and analysts evaluate the company's ability to meet its financial obligations and manage its capital structure. Positive financing cash flow indicates that the company has access to capital markets and can raise funds to support its growth. Conversely, negative financing cash flow suggests that the company may be facing challenges in meeting its financial obligations or raising capital. Marinus Pharmaceuticals Inc's financing cash flow provides insights into its financial strategy and its ability to secure funding for its operations and growth initiatives.
Free cash flow is a critical financial metric for evaluating Marinus Pharmaceuticals Inc's (MRNS) financial performance. It represents the cash flow available to the company after deducting capital expenditures required to maintain or expand its asset base. Free cash flow is calculated by subtracting capital expenditures from cash flow from operating activities. Positive free cash flow indicates that the company can generate cash from its operations and fund its capital expenditures. It provides insights into the company's ability to invest in growth opportunities, pay dividends, reduce debt, and return value to shareholders. Marinus Pharmaceuticals Inc's free cash flow serves as an important indicator of its financial health and ability to generate cash.
The investing cash flow of Marinus Pharmaceuticals Inc (MRNS) represents the cash flow resulting from the company's investing activities. It includes cash inflows and outflows related to the purchase or sale of long-term assets, such as property, plant, and equipment, as well as investments in other companies. Analyzing the investing cash flow helps investors and analysts evaluate the company's capital allocation strategy and its ability to make strategic investments. Positive investing cash flow suggests that the company is investing in assets that will support its future growth and profitability. Negative investing cash flow may indicate divestment or a lack of investment opportunities. Marinus Pharmaceuticals Inc's investing cash flow provides insights into its investment decisions and its long-term growth prospects.
The operating cash flow of Marinus Pharmaceuticals Inc (MRNS) represents the cash flow resulting from the company's core operating activities. It includes cash inflows and outflows related to the production and sale of goods and services. Analyzing the operating cash flow helps investors and analysts assess the company's ability to generate cash from its core operations. Positive operating cash flow indicates that the company can generate cash to support its day-to-day operations, invest in growth opportunities, and meet its financial obligations. Negative operating cash flow may suggest challenges in generating sufficient cash from operations or managing working capital. Marinus Pharmaceuticals Inc's operating cash flow provides valuable insights into its financial performance and its ability to generate cash from its core operations.
add Marinus Pharmaceuticals  to watchlist

Keep an eye on Marinus Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level